The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
Open Access
- 31 May 2008
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 44 (7), 912-920
- https://doi.org/10.1016/j.ejca.2008.01.005
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast CancerJournal of Clinical Oncology, 2006
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vesselsAngiogenesis, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Tumor angiogenesis and accessibility: Role of vascular endothelial growth factorSeminars in Oncology, 2002
- The vascular endothelial growth factor family; proteins which guide the development of the vasculatureInternational Journal of Experimental Pathology, 1998
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochemical and Biophysical Research Communications, 1992
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992